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a b s t r a c t
Fornearly twodecadesmost researchonBARD1was closely linked to researchonBRCA1, thebreast cancer
predisposition gene. The co-expression of BARD1 and BRCA1 genes in most tissues, the nearly identical
phenotype of Bard1 and Brca1 knock-out mice, and the fact that BRCA1 and BARD1 proteins form a stable
complex, led to the general assumption that BARD1 acts as an accessory to BRCA1. More recent research
on both proteins showed that BRCA1 and BARD1 might have common as well as separate functions.eywords:
ancer biomarker
lternative splicing
ancer predisposition
ompeting endogenous RNA
This review is an overview of how BARD1 functions and controls BRCA1. It highlights also experimental
evidence for dominant negative, tumor promoting, functions of aberrant isoforms of BARD1 that are
associated with and drivers of various types of cancer.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ancer treatment
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. BARD1 the major binding partner of BRCA1
In a yeast 2-hybrid screen to identify proteins that associate
ith the BRCA1 protein in vivo, the most promising candidate
dentiﬁed was a novel protein that interacted with the N-terminal
egion of BRCA1 and which was named BRCA1-Associated RING
omain-1, or BARD1 (Wu et al., 1996). The human BARD1 gene
as mapped close to the telomeres of chromosome 2 to 2q34-q35
Wu et al., 1996), composed of 11 exons, and encoded a protein
f 777 amino acids. BRCA1, located to chromosome 17, is com-
osed of 24 exons and encodes a 1863 amino-acid protein (Miki
t al., 1994). BARD1 has sequence and structural similarities with
RCA1, but not with BRCA2, the second breast cancer suscepti-
ility gene (Wooster et al., 1994) (Fig. 1). BARD1 is speciﬁcally
omologous to BRCA1 within the conserved RING ﬁnger domain
t the N-terminus (residues 46–90) (Brzovic et al., 2001a) and
he two tandem BRCA1 carboxy-terminal (BRCT) domains at its
-terminus (residues 616–777) (Bork et al., 1997). BRCA1 and
ARD1 can form homodimers via their RING ﬁngers, but they pref-
rentially form more stable heterodimers, implicating residues
–109 of BRCA1 and residues 26–119 of BARD1 (Meza et al.,
999), and when hetero-dimerized the RING domains have E3
biquitin ligase activity (Brzovic et al., 2001b; Hashizume et al.,
001).
The BRCT repeats are deﬁned by a speciﬁc conserved tertiary
tructure (Glover et al., 2004) and have been identiﬁed in many
NA damage repair and cell cycle checkpoint proteins (Callebaut
nd Mornon, 1997; Huyton et al., 2000). The BRCT modules can
orm homo/hetero BRCT multi-dimers, BRCT-non-BRCT dimers,
nd interact with DNA strand breaks (Huyton et al., 2000). Inter-
stingly, mutations in BRCA1 that cause truncation or loss of both
RCT domains are associated with cancer, suggesting that BRCTs
re essential for tumor suppressor functions (Glover et al., 2004;
ayes et al., 2000; Huyton et al., 2000; Williams and Glover, 2003).
he BRCT domains of BRCA1 have transcription transactivation
ctivity (Monteiro et al., 1996) and function as phospho-epitope
inding domain (Glover et al., 2004; Rodriguez et al., 2003; Yu
t al., 2003). In particular it was shown that BRCA1 via its BRCT
omain binds to the phosphorylated BRCA1-Associated Carboxyl-
erminal Helicase (BACH1) or also called BRIP1 (Yu et al., 2003).
he interaction of BARD1 with these phospho-proteins has only
een demonstrated in vitro (Thanassoulas et al., 2010). However,
he BARD1 BRCT domains interact with a variety of proteins, as
iscussed below.
In addition to RING and BRCT domains, BARD1has three ankyrin
ANK) repeats (residues 427-525) located upstream of the BRCT
omains, and these are the most conserved region of the BARD1
rotein (Ayi et al., 1998; Irminger-Finger et al., 1998) (Fig. 2). A
orth, less conserved, ANK repeat was also described (Fox et al.,
008). Varying numbers of ANK repeats are found in many pro-
eins, including Notch, NF-kB, TP53BP, and ankyrins, and mediate
rotein-protein interactions. The ANK repeats in BARD1 are most
omologous with the ANK sequences of TP53BP (Irminger-Finger,
npublished). Several protein interactions have been reported
etween the BARD1 ANK repeats, including p53 (Feki et al.,
005; Irminger-Finger et al., 2001; Jefford et al., 2004) and NF-B
Dechend et al., 1999). The combination of RING, ANK, and BRCT
omains is a unique feature of BARD1 and not found in any other
rotein.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Human BARD1 has a nuclear export signal (NES) (residues
102–120) (Rodriguez et al., 2004) and six predicted nuclear local-
ization signals (NLS), situated close to the functional domains
(Jefford et al., 2004; Schuchner et al., 2005). NLS and NES are criti-
cal for proper intracellular localization of BARD1 and BRCA1, thus
affecting their functions.
BARD1 orthologues, beside mouse (Ayi et al., 1998; Irminger-
Finger et al., 1998) and rat (Gratas et al., 2001), were reported for
Xenopus laevis (Joukov et al., 2001), Caenorhabditis elegans (Boulton
et al., 2004), and Arabidopsis thaliana (Lafarge and Montane, 2003)
and showed conservation of sequence and exons structure (Fig. 2).
Interestingly, the sequence of BARD1 Canis lupus exon 1 lacks any
similarity with other known BARD1 sequences and encodes an
incomplete RING ﬁnger (Irminger-Finger unpublished). Sequence
data of more than 20 species corroborate the evolutionary conser-
vation of BARD1, but less so for the 5′exons, encoding the BRCA1
interaction (Fig. 2).
2. Similar phenotypes of BARD1 and BRCA1 gene
knock-outs
The knockout of Brca1 or Brca2 genes in mice led to embryonic
lethality (Gowen et al., 1996; Hakem et al., 1996, 1998; Ludwig
et al., 1997). Similarly, theBard1-nullmouseembryosdiedbetween
embryonic days E7.5 and E8.5 and showed cell proliferation defects
and genomic instability (McCarthy et al., 2003). Partial rescue was
obtained in Bard1−/−;p53−/− double knockout embryos, which
survived until day E9.5. The Bard1−/−;p53−/− cells displayed an
increaseof structural andnumerical chromosomeaberrations com-
pared to p53−/− cells. The phenotypes of Bard1 knockout mice
demonstrated that BARD1 is essential for cell viability and main-
tenance of genome integrity. It remained unexplained why the
depletionof BARD1 leads to lethality only after eight days of embry-
onic development. Interestingly, Bard1, as well as Brca1 and Brca2
knockout embryos die at the time when Bard1, but not Brca1,
expression ismaximal,which suggests a complex systemofmutual
regulation of gene expression (Irminger-Finger et al., 1998; Joukov
et al., 2001).
Mice with conditional Cre recombination-dependent d of either
Bard1 or Brca1 in mammary epithelial cells developed breast
cancers that resembled the human triple negative breast cancer
phenotype seen in carriers ofBRCA1mutations (Shakya et al., 2008).
However, Bard1 as well as Bard1/Brca1 double mutants showed
both faster initiation of breast cancers than Brca1 mutants, sug-
gesting a dominant role of BARD1.
Northern blot experiments showed that murine Bard1 mRNAs
wereonly expressed in spleenand testis (Ayi et al., 1998).More sen-
sitive RNase protection experiments showed expression in most
proliferating tissues of the mouse and most elevated in testis
and spleen (Irminger-Finger et al., 1998). Bard1 was also highly
expressed during embryogenesis, with a maximum at day 11
(Irminger-Finger et al., 1998), consistentwith the embryonic letha-
lity phenotype. More complete expression data are available at
Gene Expression website ASAP II or GeneCards.org.
During embryogenesis, Bard1 and Brca1 transcripts were co-
ordinately expressed until embryonic day 11 and are differentially
expressed thereafter and in hormonally controlled organs of
adult female mice (Irminger-Finger et al., 1998). In testis, Bard1
was expressed at all stages of spermatogenesis, whereas Brca1
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Fig. 1. Comparison of protein structures of BARD1, BRCA1 and BRCA2. RING (green), ankyrin (blue), BRCT (red) domains, nuclear export signal (NES, brown), and potential
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puclear localization signals (NLS, light blue) are indicated. The third NLS (at amino
ompletely unrelated to either BARD1 or BRCA1 with conserved transactivation dom
f the references to color in this ﬁgure legend, the reader is referred to the web ver
xpressionwas only seen inmeiotic and early round spermatocytes
Feki et al., 2004; Scully et al., 1997). These observations were ﬁrst
ndications of commonand separate functions of BARD1 and BRCA1.
More recent work showed that rather the BRCA1 C-terminus
han the RING ﬁnger is important for tumor suppression (Shakya
tal., 2011). TheabsenceofE3 ligaseactivity, speciﬁedby theBRCA1
nd BARD1 RING ﬁngers, did not lead to tumor formation in mice,
ut mutations in the BRCA1 BRCT domain induced tumors (Shakya
t al., 2011).
Similarly, alleles of the BARD1 homologue of Arabidopsis lack-
ng N-terminal domains showed no phenotype, while the deletion
f the C-terminal domain led to severe defects of the shoot apical
eristem (SAM) (Reidt et al., 2006). As SAM is the stemcell organiz-
ng center in plants (Han et al., 2008), these analyses demonstrated
function of BARD1 in regulating the positioning of stem cells and
aintenance of SAM.
. Cellular functions of BARD1 and BRCA1
BARD1 and BRCA1 proteins are synthesized during the S phase
f the cell cycle (Hayami et al., 2005) and co-localizewith the repair
rotein Rad51 in nuclear dots (Jin et al., 1997). This co-localization
f BARD1 and BRCA1 with Rad51 at sites of DNA damage suggested
function of the BARD1-BRCA1 heterodimer in DNA repair (Stark
t al., 2004; Westermark et al., 2003) and triggered research inves-
igating BRCA1 and BARD1 DNA repair functions.
However, BARD1 is also required for normal cell viability, as
emonstrated with the Bard1 knockout mice (McCarthy et al.,
003). In vitro repression experiments showed that BARD1 deﬁ-
iency leads to defects in S-phase progression, loss of contact
nhibition of growth, and genetic instability (Irminger-Finger et al.,
998).
BARD1 has speciﬁc roles in cell cycle progression, with BRCA1
nd distinct from BRCA1. BARD1 plays a chaperone role for BRCA1
ranslocation into (Fabbro et al., 2002) and retention in the nucleus
Brzovic et al., 2001a; Fabbro et al., 2002; Schuchner et al., 2005),
s BRCA1-BARD1 hetero-dimerization masks the NES of both pro-
eins, causing their nuclear retention of the BRCA1-BARD1 complex
Jefford et al., 2004; Rodriguez et al., 2004).
During the cell cycle, at onset of mitosis, BRCA1 controls cen-
rosome duplication (Hsu and White, 1998; Starita et al., 2004; Xu
t al., 1999). The localization of BRCA1 to the centrosome depends
n BARD1 and the Ran GTPase (Joukov et al., 2006), and centro-
ome duplication control depends on phosphorylation of BRCA1
y the Aurora A kinase and OLA1 (Brodie and Henderson, 2012a;
atsuzawa et al., 2014; Ouchi et al., 2004; Sankaran et al., 2007).
he function of BARD1-BRCA1 heterodimer in the regulation of
entrosome ampliﬁcation requires the nuclear export of BRCA1,
romoted by a nuclear export receptor and competed for by BARD1eside 321) of BARD1 is most important for nuclear localization of BARD1. BRCA2 is
D) and 8 copies of a 70 amino acid motif called the BRC repeats. (For interpretation
f this article.)
(Brodie and Henderson, 2012b; Brodie et al., 2012). At later stages
of mitosis it is BARD1 is essential for the completion of cytokinesis
by dissociating fromBRCA1 and interactingwith BRCA2 andAurora
kinase B, independently of BRCA1 (Ryser et al., 2009).
A cytoplasmic localization of BARD1 was associated with its
apoptotic function and observed after the proteolytic cleavage of
BARD1 (Gautier et al., 2000; Jefford et al., 2004; Rodriguez et al.,
2004). Thus there is a dynamic interplay of BARD1 and BRCA1 in
translocation to DNA repair sites and in shuttling in and out of the
nucleus.
BRCA1 and BARD1 have also functions in the regulation of chro-
matin condensation. In particular they interact with the inactive
X chromosome (Xi)-speciﬁc transcript (XIST) RNA, a non-coding
RNA known to coat Xi and to participate in the initiation of its inac-
tivation during early embryogenesis (Ganesan et al., 2004). Female
somatic cells lacking wild-type BRCA1, or BRCA1-depleted cells,
cannot localize XIST RNA to Xi, but the exogenous expression of
wild-type BRCA1 can correct this defect. However, BRCA1-deﬁcient
breast cancer cell lines did not show changes of XIST RNA concen-
tration on Xi (Silver et al., 2007; Xiao et al., 2007). Despite these
controversial observations, BRCA1 and BARD1 may play a role in
the regulation of XIST localization and concentration on Xi and in
maintaining heterochromatin structure or function.
These speciﬁc individual functions of BRCA1 and BARD1, their
interactions with various proteins (Fig. 3), as well as the dissoci-
ation of the heterodimer, might be regulated by posttranslational
protein modiﬁcations such as phosphorylation, ubiquitination, or
parsylation.
4. The BARD1-BRCA1 heterodimer is an E3 ubiquitin ligase
with multiple functions
Better understanding of BRCA1 and BARD1 functions as het-
erodimer, camewith thediscoveryof theE3ubiquitin ligaseactivity
of the BRCA1-BARD1 heterodimer (Hashizume et al., 2001). Ubi-
quitin ligases initiate polyubiquitination, which marks proteins
for degradation by the proteasome. Mutations in the BRCA1 RING
domain that disrupt the E3 ubiquitin ligase activity of BRCA1-
BARD1 are predisposing to breast and ovarian cancer (Brzovic et al.,
2001a; Hashizume et al., 2001; Ruffner et al., 2001).
Polyubiquitin chains are commonly K48-linked. The
BRCA1–BARD1 heterodimer directs ubiquitin polymerization
through K6 linkage on various proteins, including auto-
ubiquitination of BARD1 and BRCA1 (Chen et al., 2002; Wu-Baer
et al., 2003) (Table 1). However, auto-ubiquitination does not
result in degradation of BARD1 or BRCA1, but in an increase of
ubiquitin ligase activity and stability of BARD1-BRCA1 (Chen et al.,
2002; Mallery et al., 2002; Wu-Baer et al., 2003) and increased
DNA damage response (Sankaran et al., 2006).
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348
350
374
338
QIESPDTKSRNEVVT-PEK-VCKNYLT-S-----KKSLPLE---NNGKRGH--HNRLSSPISKRCRTSILSTSGDFVKQT----VPSENIPLP-------
HIESPEIESKNEVVT-PEKTVSANYLP-S-----KKSLPSG---RNGKRGR--HNRISSPVSKRCRSSSQSTGGNSVKQT----VLLENMPLL-------
QIESPELESRNEELT-PQKNLCENPLP-P-----KQSLPSG---HSGRRGR--RSSRSSPISKRCRSSIPGTSS---QHI----VLSESKPLP-------
HIESPETESKNEAVT-PEKTLCENVLDES-----KKSLPSR---HNGNRGC--RSRLTSPVSKRCRNSIPSTSGNSVKQT----VLSENVPSP-------
HIVSPDTVSKNEET--PEKKVCVKDL-----------RSGG---SNGNRKG--CHRPTTSTSDSCGSNIPSTSRGIGEPA----LLAENVVLV-------
HIVSPDTVSKSEEA--PEKKVCVEDR-----------CPVG---SDGNPKG--CHRPPTSTSKKCGSNVPSASGEIREPT----LLAENVVLV-------
QADSVEMDRDSEVASSHPESFCEDNFT-S-----ETSLPLR---NGGAWERQQPNSFVVPVSKRPRRRR---SQQRVRRA----SLSSDVPLESLTPREE
-EVSPEVKSSQEED--NSKAVCPVQVSKETNCAAEKSPSIESKAMHLKRGREQSKLPGTSQTKRRRS-EGSLNRNSDSQTSCSEDLSQDCPIPQVT----
BRCT2
777
772
912
788
765
768
799
750
Homo_sapiens
Bos_taurus
Canis_lupus_familiaris
Sus_scrofa
Mus_musculus
Rattus_norvegicus
Monodelphis_domestica
Gallus_gallus
743
738
878
754
731
734
765
717
CNYHPERVRQGKVWKAPSSWFIDCVMSFELLPLDS
SNHRPERVRQGKVWMAPSSWFIDCVMSFELLPLDN
SNHHPKRVRQGKVWMAPSSWFIDCVMSFELLPLDS
SNHRPERVRQGKVWMAPSSWFIDCVMSFELLPLDS
FNCHPERVRQGKVWMAPSTWLISCIMAFELLPLDS
FNCHPERVRQGKVWMAPSTWLISCVMAFELLPLDS
SNYHPERVRQGKVWMAPSNWFIDCLMAFQVLPVTK
SKFKPEKIRQGKVWFAPSSWIVDCIMSFQLLPVK-
RING
Homo_sapiens
Bos_taurus
Canis_lupus_familiaris
Sus_scrofa
Mus_musculus
Rattus_norvegicus
Monodelphis_domestica
Gallus_gallus
1
1
181
1
1
1
1
1
95
90
229
90
89
89
95
66
MPDNRQPRNRQPRIRSGNEPRSAPAMEPDG-----RGAWAHSRAALDRLEKLLRCSRCTNILREPVCLGGCEHIFCSNCVSDCIGTGCPVCYTPAWIQDL
-----MQGNRQPRVRSGNQPHPAPAMKPAG-----RGAWAHSRAALDRLEKLLRCSRCTNILREPVCLGGCEHIFCSNCVSDCIGSECPVCYTPAWIQDV
---------------------------------------------------FSFSSNSSNILREPVCLGGCEHIFCSNCVSDCIGTGCPVCYTPAWIQDV
-----MPGNRLPRVRSGNEPHPAPSMEPAG-----RGAWAHSRAALARLEKLLRCSRCTDILREPVCLGGCEHIFCSNCISDCFGSGCPVCYTPAWIQDV
------MPRRPPRVCSGNQPAPVPAMEPAT-----DGLWAHSRAALARLEKLLRCSRCANILKEPVCLGGCEHIFCSGCISDCVGSGCPVCYTPAWILDL
------MPRRPPRVCSGNKPPPVPAMEPAT-----DGLWAHSRAALARLEKLLRCSRCANILREPVCLGGCEHIFCSGCISDCVGSGCPVCHTPAWILDL
-----MQRDQPLKVRSGNEQWPESSMQPAGGGGVGAGAWNHSREALELLETQLRCSRCLNILREPVCLGGCEHIFCSVCVGDCIGTECPVCHTPAWIQDV
----------------------------------MARPWAHTRAALERLERALSCSRCAGVLREPVSLGGCEHVFCLSCMGDHVGKGCPVCHVPAWVQDM
Ex. 1 Ex. 2 Ex. 2 Ex. 3
Homo_sapiens
Bos_taurus
Canis_lupus_familiaris
Sus_scrofa
Mus_musculus
Rattus_norvegicus
Monodelphis_domestica
Gallus_gallus
96
91
230
91
90
90
96
67
190
186
325
186
183
185
190
159
KINRQLDSMIQLCSKLRNLLHDNELSDLKEDKPRKS----LFNDAGNKKNSIKMWFSPRSKKVRYVVSKASVQTQPAIKKDASAQQ-DSYEFVSPSPPAD
KINRQLDSMIQLCSKLQNLLHDTDLSDLKEKTSRKS----LFNDAQSKKNSIKMWFSPRSKKVRYTVSKLSVQTQPSVKNDENAQQTSMYEFVSPSPPVE
KINRQLDSMIQLCSKLRNLLHDDKLSDLKEDTSREN----LFNDAENKKNSIKMWFSPRSKKVRYVVSKVSVQTHPQVISDENARQASMYEFVSTSPPTS
KINRQLDSMIQLCSKLRNLLHDADSSDLKEETSRKS----LFSDAEYKKNSIKMWFSPRSKKVRYVVSKVSVQTHPPMINDENAQQASLYEFVSTSPPVD
KINRQLDSMIQLSSKLQNLLHDNK--DSKDNTSRAS----LFGDAERKKNSIKMWFSPRSKKVRYVVTKVSVQTQPQKAKDDKAQEASMYEFVSATPPVA
KINRQLDSMIQLYSKLQNLLHDNKGSDSKDDTSRAS----LFGDAERKKNSVKMWFSPRSKKIRCVVNKVSVQTQPQKAKDDKAQEASVFEFVSATPPVV
KINRQLDNMIQLCSRLRNLLHNTTGTDEEESTPRTRA---SLDEDENNKKFIKMWFSPRSKKVRYVLNKTLVQTQPQPVENE--QDYQAFEFSSSSLEKD
QINRQLDDMVQLCGKLRHLLDAGTSD-SMESTPTPMC---SDFGENSKKGQIKMWFSPRSRKIRCIVNKNQPKTNSNDLC---QDPSSVYHFFPSPVHEK
Ex. 3 Ex. 4
ANK1
Homo_sapiens
Bos_taurus
Canis_lupus_familiaris
Sus_scrofa
Mus_musculus
Rattus_norvegicus
Monodelphis_domestica
Gallus_gallus
361
355
494
359
349
351
375
339
443
439
578
454
431
433
464
418
ECSS--PPSCKRKVGGTSGRKNSN--MSDEFISLSPGTPPSTLSSSSYRQ-------VMSSP-SAMKLLP--NMAVKRNHRGETLL---HIASIKGDIPS
GCSS--PPSNKLKVGDTLSRNSRT--ILDESISLSPGTPPSTLNSPSYRR-------MMCSP-SATKLWPISHTAVKRNHRGETLL---HIASIKGDIPS
GCSS--PPSSKLKIGDTLRRKNSN--LSVESMTLSPGTPPSALNSPRYRR-------MMSSP-SATKLSPNSLTAVKRNHRGETLL---HIASIKGDVPS
GCSS--PPSNKLKRGATLRRKTSN--ILDESISLSPGIHTPFYTEWSLYSSYTEFSVIMGLQASQLDFGHLAPFEQRRRRKYDKLLNTREEKADQGDVPS
DCSS--LPSGQLQVDVTLRRK-SN--ASDDPLSLSPGTPPPLLNNSTHRQ-------MMSSPS-TVKLS-SGMPARKRNHRGETLL---HIASIKGDIPS
DCSS--LPSGRLQVDVTLRRQ-SN--ASDDSLSLSPGTPPSLLNNSTHRQ-------MMSKPS-TVKLS-SGIPARKRNHRGETLL---HIASIKGDISS
SAPS--PTSKSLADEPFLRVRNSD--VLNDSINFSPHKSSGTSSSSLLNSPCQP--WIVSSP-SVVKMSPTSPMTVKRNHRGETLL---HIASIKGDIPS
---E--PRTPVQVCGSAMKTRSSA--ASSPLLPKSPSTPSTFK-------ACDQVG-IPQS--PSVFKSPGSNPIARRNYKGETLL---HIASIKGDLAA
Ex. 4 Ex. 5
BRCT1
Homo_sapiens
Bos_taurus
Canis_lupus_familiaris
Sus_scrofa
Mus_musculus
Rattus_norvegicus
Monodelphis_domestica
Gallus_gallus
544
540
679
555
532
534
565
519
642
637
777
653
630
633
664
616
LLPEKNESSSASHCSV-MNTGQRRDGPLVLIGSGLSSEQQKMLSELAVILKAKKYTEFDSTVTHVVVPGDAVQSTLKCMLGILNGCWILKFEWVKACLRR
LLPEKEEISSLSH-SV-VKTGQRRDGPLVLIGSGLSSEQQKMLSELATILKAKKCAEFDGTVTHVIVPGDTVQSTLKCMLGILSGCWILKFEWVKACLQS
LLPEKNESSSTRHYSV-PNTGQRRDGPLVLIGSGLSSEQQKMLSELAAILKAKKCAEFDNTVTHVIVPGDTVQSTLKCMLGILNGCWILKFEWVKACLQR
LLPEKDESSSTSHCSA-VNTGQRRDGPLVLIGSGLSSEQQKMLSELAAMLKAKKCAEFDSAVTHVVVPGDTVQSTLKCMLGILSGCWILKFEWVKACLQR
LLPEENESFSTSQCSI-VNTGQRKNGPLVFIGSGLSSQQQKMLSKLETVLKAKKCMEFDSTVTHVIVPDEEAQSTLKCMLGILSGCWILKFDWVKACLDS
LLPEKTDSFSTSQCSVQVNTGQRKSGPLVLIGSGLSSQQQKLLSKLETVLKAKKCAEFDNTVTHVIVPDEEAQSTLKCMLGILNGCWVLKFDWVKACLDS
LLPEESEIYEIGQCSKSLNTSYRRDDPLVLLSSGLTSDQQKLLSKLSAVLKAKKCTEFNSMVTHIIVPGDTAQRTMKCILGIISGCWILKFDWVKACLES
MLPVKNESFSFSQPSE--SPSQPRDGPLGILGSGLSSKQQKLLNKLATVLKARRCTEFNSTVTHVVVPDVPMPSTVKCMMAVLSGCWVLKFEWVQACLQS
Ex. 7 Ex. 8 Ex. 8 Ex. 9 Ex. 9 Ex. 10
ANK2 ANK3
Homo_sapiens
Bos_taurus
Canis_lupus_familiaris
Sus_scrofa
Mus_musculus
Rattus_norvegicus
Monodelphis_domestica
Gallus_gallus
444
440
579
455
432
434
465
419
543
539
678
554
531
533
564
518
VEYLLQNGSDPNVKDHAGWTPLHEACNHGHLKVVELLLQHKALVNTTGYQNDSPLHDAAKNGHVDIVKLLLSYGASRNAVNIFGLRPVDYTDDESMKSLL
VEYLLQSGSDPNVKDHAGWTPLHEACNHGHLKVVELLLQHKALVNTTGYQNDSPLHDAVKNGHVDIVKLLLTYGASREAVNIFGLRPVDYADSENMKSLL
VEYLLQNGSDPNVKDHAGWTPLHEACNHGHLKVVELLLQHQALVNTPGYQNDSPLHDAARNGHLEIVKLLLASGASRDAVNIFGLRPVDYADNENMKSLL
VEYLLGNGSDPNVKDHAGWTPLHEACSHGHLKVVELLLQHKALVNTTGYQNDSPLHDAVKNGHVDIVKLLLSYGASRNAVNIFGLRPVDYTDSENMKSLL
VEYLLQNGNDPNVKDHAGWTPLHEACSHGHLKVVELLLQHNALVNTPGYQNDSPLHDAVKSGHIDIVKVLLSHGASRNAVNIFGVRPVDYTDNENIRSLL
VEYLLQNGNDPNVKDHAGWTPLHEACSHGHLKIVELLLQHNALVNTTGYHNDSPLHDAAKNGHIDIVKVLLSHGASRNAVNIFGERPVDYTDAENIRSLL
VERLLQNGSDPNVKDHAGWTPLHEACNHGHQKVVELLLEHKALVNTTGYQNDSPLHDAVRNGHVSIAKLLLSHGASRSAVNIFGLRPVDYAETEAMKSVL
VEELLKNGADPNVKDNAGWTPLHEACNHGHQEVVELLLQHKALVNSTGYQNDSPLHDAAKNGHVSIVELLLLHGASRDAVNIFGLRPVDYAESEKMKSVL
Ex. 5 Ex. 6 Ex. 6 Ex. 7
ANK1
BRCT2
Homo_sapiens
Bos_taurus
Canis_lupus_familiaris
Sus_scrofa
Mus_musculus
Rattus_norvegicus
Monodelphis_domestica
Gallus_gallus
643
638
778
654
631
634
665
617
742
737
877
753
730
733
764
716
KVCEQEEKYEIPEGPRRSRLNREQLLPKLFDGCYFYLWGTFKHHPKDNLIKLVTAGGGQILSRKPKPDSDVTQTINTVAYHARPDSDQRFCTQYIIYEDL
KECEQEEKYEIPEGPQKSRLNREQLLPKLFDGCYFYLGGTFKHHPKDNLIKLVAAGGGQILIRKPKPDSDVTQSINTVAYHAKPDSDQRFCTQYIIYEDL
KACEQEEKYEIPEGPHRSRLNKEQLLPKLFDGCYFYFGGTFKHHPKDNLIKLVTAAGGQVLSRKPKPDSDVTQTINTVAYHARPDSDQRFCTQYIIYEDL
KKCEQEEKYEIPEGPRRSRLNREQLLPKLFDGCYFYFGGTFKHHPKDNLIKLVTAAGGQILSRKPKPDSDVTQTINTVAYHAKPDSDQRFCTQYIIYEDL
KVREQEEKYEVPGGPQRSRLNREQLLPKLFDGCYFFLGGNFKHHPRDDLLKLIAAAGGKVLSRKPKPDSDVTQTINTVAYHAKPESDQRFCTQYIVYEDL
QEREQEEKYEVPGGPQRSRLNREQLLPKLFDGCYFFLGGNFKHHPKEDLLKLIAAAGGRILSRKPKPDSDVTQTINTVAYHAKPDSDQRFCTQYIVYEDL
RMCEPEEKYEILGGPQRSRLNREQLLPKLFDGCYFYFEGIFKHHSKDELVKLAKESGGQILNRKPKPDSDVTQTINTVSYHARPDSDQRFCTQYIIYDAF
TVREQEEKYEIQGGPQRGRLNREQLLPKLFDGCYFYFLGSFNSHQKSDLVELVKAGGGQILVRQPKPDSDVTQTINTVAYHAESTSDQRFCTQYVIYDAS
Ex. 10 Ex. 11
BRCT1
A
Fig. 2. BARD1 is conserved between species. The human BARD1 protein (hBARD1) sequence was aligned with the BARD1 proteins of different species using Clustal Omega
multiple sequencealignment tool (http://www.ebi.ac.uk/Tools/msa/clustalo/), andvisual representationwasdoneusing Jalviewsoftware (www.jalview.com). Thealignments
are color coded in shades of blue for the percentage identity. The exon junctions of hBARD1 are indicated with arrows. The functional domains of BARD1 were deﬁned with
the use of the SMART motifs search web tool (http://smart.embl-heidelberg.de/), indicated with overlaid bars: RING (red), ANK (green), BRCT (blue). Human BARD1 aligned
with mammalian A) and other (B-D) species. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 2. (Continued )
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Fig. 3. Proteins interacting with the BARD1-BRCA1 complex or BARD1. BRCA1 and BARD1 are shown with RING, BRCT, and ANK domains indicated. BARD1 has been shown to
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Tnteract with a number of proteins in its role as E3 ubiquitin ligase (orange), as BRCA
egion of interaction. BAP1 binds to BRCA1 and BARD1 and inhibits ubiquitin ligase
eferred to the web version of this article.)
Heterodimer formation and ubiquitination are positive reg-
lators of the BRCA1-BARD1 ubiquitin ligase activity, while
hosphorylation of BARD1 by CDK2 and CDK1 on its NH2 terminus
ompletely abolishes the ubiquitin ligase activity (Hayami et al.,
005). The BRCA1 associated protein 1 (BAP1), a de-ubiquitinating
nzyme (DUB), also inhibits the E3 ligase activity of BRCA1-BARD1
Nishikawa et al., 2009). BAP1 interacts with the RING ﬁnger of
RCA1 and BARD1 and functions in growth control (Jensen et al.,
998; Mallery et al., 2002; Nishikawa et al., 2009).
A number of potential substrates of the BARD1-BRCA1 E3 ubi-
uitin ligase were discovered by a quantitative approach (Song
t al., 2011), but have not been functionally tested.
.1. BARD1-BRCA1 E3 ligase activity in the DNA damage response
athwayThe dissection of DNA repair pathways showed a major role for
he BRCA1-BARD1 heterodimer in homologous repair (Stark et al.,
004). The biochemically deﬁned cellular complex associated with
NA damage response and retaining E3 ubiquitin ligase activity,
able 1
argets of the BARD1-BRCA1 ubiquitin ligase.
Target Linkage Effect F
Histone H2A
Histone H2AX
Histone H2B
Monoubi. Stabilization C
RNA polymerase II Polyubi. Degradation I
Topisomerase II ND Modiﬁed H
Nuleophosmin NPM/B23 Monoubi. Stability A
-tubulin Polyubi. Degradation M
c
TPX2 ND S
Aurora A Polyubi. Degradation R
m
Aurora B Polyubi. Degradation R
m
Estrogen receptor  Polyubi. Degradation R
g
Progesterone Receptor Polyubi. Degradation R
g
BRCA1
BARD1
Monoubi. Stability SRD1 complex (blue), or in a BRCA1- independent manner (green) with approximate
ity. (For interpretation of the references to color in this ﬁgure legend, the reader is
contained BRCA1, BRCA2, BARD1, and RAD51, as well as BRE and
BRCC36, all essential for E3 ligase activity andDNA repair following
DNA damage, and was named the BRCA1-BRCA2 containing complex
(BRCC) (Dong et al., 2003).
BRCA1 and BARD1 also interact with the DNA mismatch repair
(MMR) genes, known as predisposition genes for colon cancer
(Rustgi, 2007), and bind to MSH2 and MSH6 in vitro and in vivo
(Wang et al., 2001) and might act as downstream effectors of the
MSH2-MSH6 complex in DNA mismatch repair signaling.
The BRCA1-BARD1 complex has a role in repair of double strand
breaks (DSBs) by regulating the activity of topoisomerase II (topo
II ) in an ubiquitination-dependent manner (Shinagawa et al.,
2008; Sordet et al., 2008). Ubiquitination of topo II  by BRCA1-
BARD1was speciﬁcally inducedbyhypoxia,which also upregulates
BARD1 expression (Irminger-Finger et al., 2001; Li et al., 2007a).
Many cancer drugs are designed to inhibit topisomerase I or II, and
deﬁciencies of BRCA1 or BARD1 might enhance the efﬁcacy of this
treatment.
It was shown that BRCA1-BARD1 was responsible for ubiquit-
ination of phosphorylated RNA Pol II in response to DNA damage
unction Reference
hromatin modiﬁcation (Calvo and Beato, 2011; Chen et al., 2002;
Mallery et al., 2002; Thakar et al., 2010; Xia
et al., 2003)
nhibition of transcription (Kleiman et al., 2005; Starita et al., 2005)
elicase function in repair (Shinagawa et al., 2008)
poptosis control (Sato et al., 2004)
icrotubule nucleation,
entrosome ampliﬁcation
(Sankaran et al., 2005; Starita et al., 2004)
pindle orientation (Joukov et al., 2006)
egulator of
itosis/anaphase
(Bosse et al., 2012)
egulator of
itosis/cytokinesis
(Bosse et al., 2012; Ryser et al., 2009)
egulation ER response
enes
(Dizin and Irminger-Finger, 2010; Eakin et al.,
2007)
egulation of PR response
enes
(Calvo and Beato, 2011)
tability, increase activity (Chen et al., 2002; Choudhury et al., 2004;
Hayami et al., 2005; Wu-Baer et al., 2003)
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Kleiman et al., 2005; Starita et al., 2005), a critical step in a genome
urveillance pathway. Depletion of BRCA1 or BARD1 reduced the
biquitinationof RNAPol II afterDNAdamage, andover-expression
f BRCA1 in cells stimulated the ubiquitination of RNA Pol II
nd recovery of cells after exposure to DNA damage (Sankaran
t al., 2005). These ﬁndings implicate that the BARD1-BRCA1 het-
rodimer is involved in the regulation of transcription in response
o DNA damage.
.2. BARD1-BRCA1 E3 ligase function in modulating chromatin
tructure
The BRCA1-BARD1 ubiquitin ligase also targets the nucleosome
ore histones, and the histone variant H2AX. BRCA1 and BARD1
timulate monoubiquitination of H2A/H2AX in vitro (Chen et al.,
002; Mallery et al., 2002; Xia et al., 2003) as well as H2A and H2B
Thakar et al., 2010), which leads to alteration of chromatin struc-
ure and opens DNA for transcriptional activity. This result raises
he possibility that BRCA1-BARD1 can directly affect nucleosomal
tructure, dynamics, and function through its ability to modify
ucleosomal histones and chromatin structure.
.3. BARD1-BRCA1 E3 ligase function in cell cycle regulation
The regulation of mitosis from onset to cytokinesis is critical in
ddition to the G1/S and G2/M checkpoints. The duplication and
umber of centrosomes is important for spindle formation and for
aintaining chromosomal stability and ploidy. BRCA1 localizes to
he centrosome during mitosis and functions in centrosome ampli-
cation (Hsu and White, 1998; Xu et al., 1999). The BRCA1-BARD1
biquitin ligase directly regulates centrosome number by target-
ng -tubulin, which is important for the nucleation ofmicrotubule
olymerization (Sankaran et al., 2005; Starita et al., 2004).
The BRCA1 N-terminus and BARD1 C-terminus interact with
LA1, an ATPase 1, which also binds to -tubulin, and functional
tudies suggest that is essential for the BARD1-BRCA1 function on
-tubulin and spindle formation (Matsuzawa et al., 2014).
The nucleolar phosphoprotein nucleophosmin (NPM), or B23, a
itotic protein was identiﬁed in a screen for ubiquitin ligase tar-
ets of the BRCA1-BARD1 ubiquitin ligase. NPM/B23 is a chaperon
rotein involved in centrosome duplication and cell proliferation.
PM/B23 is stabilized by ubiquitination (Sato et al., 2004), which is
nhibited by BAP1 (Nishikawa et al., 2009). Mutations of NPM/B23
re speciﬁcally frequent and predictive markers in hematological
isorders (Yohe, 2015).
The BRCA1-BARD1 E3 ligase has functions in mitotic spindle
ssembly by accumulating themicrotubule binding protein TPX2, a
pindle organizer, on spindle poles (Joukov et al., 2006). The local-
zation of the BRCA1-BARD1 complex depends on Ran, a GTPase
ecessary for nuclear import and export, and leads to local TPX2
ccumulation. TPX2 is an activator of theAuroraAkinase (Tsai et al.,
003), which is required for centrosome ampliﬁcation, presumably
hrough the phosphorylation of BRCA1 (Ouchi et al., 2004).
BRCA1 and BARD1 are required for ubiquitination and degra-
ation of the Aurora B kinase in cytokinesis (Ryser et al., 2009).
uring the formation of the contractile ring around the midbody,
urora B is gradually degraded and becomes conﬁned to the mid-
ody (Delaval et al., 2004; Ryser et al., 2009). This localization
epends on the interaction with the microtubule binding protein
ACC1 (Delaval et al., 2004). The TACC1 protein also interacts with
ARD1 (Boulton et al., 2004). The abscission of the microtubule
ridge linking the two daughter cells at cytokinesis depends on
ACC1 and Aurora B (Delaval et al., 2004), BRCA2 (Daniels et al.,
004), and BARD1 (Ryser et al., 2009).f Biochemistry & Cell Biology 72 (2016) 1–17 7
4.4. BRCA1-BARD1 E3 ligase function in hormone signaling
BRCA1 and BARD1 were ﬁrst associated with breast cancer,
as mutation carriers are at high risk to develop breast (or ovar-
ian) cancers. The biggest risk factor for breast cancer is estrogen,
and estrogen deprivation is the preventive measure for carriers of
BRCA1 or BARD1 mutations. Estrogen acts via the estrogen recep-
tors alpha (ER) and beta in transcription activation of genes with
pro-proliferative functions.
ER has been identiﬁed as a putative substrate for the BRCA1-
BARD1 ubiquitin ligase in vitro (Eakin et al., 2007). Modulation of
BRCA1 or BARD1 levels demonstrated that the BRCA1-BARD1 com-
plex plays a role in ER ubiquitination and degradation in vivo
(Dizin and Irminger-Finger, 2010). The ER-interacting region lies
within the BARD1 C-terminus, which suggests that the BARD1 C-
terminus might have a function in target recognition. Estrogen
treatment induces BRCA1 and BARD1 transcriptional upregulation
in an ER-dependent manner, forming a positive feedback loop by
which the BRCA1-BARD1 ubiquitin ligase controls cellular levels of
ER (Dizin and Irminger-Finger, 2010). Thiswork provided amech-
anism that explains the causative link between estrogen exposure
and breast or ovarian cancer. Interestingly ER ubiquitination and
degradation is enhanced by FOXK2 interaction with BARD1 (Liu
et al., 2015).
BARD1 and BRCA1 also play a role in progesterone receptor (PR)
degradation in the absence of hormone (Calvo and Beato, 2011).
Through this function, BRCA1 and BARD1 affect PR recruitment to
target gene promoters and transcription. The BRCA1-BARD1 com-
plex interacts and translocates with PR to the hormone-responsive
regions of PR target genes and acts in mono-ubiquitination of
histone H2A and thus contributes to epigenetic silencing of the
respective promoters. Thus, the BRCA1-BARD1 heterodimer reg-
ulates transcription of PR response genes in a hormone-dependent
and independent manner.
5. BRCA1-independent BARD1 interactions and pathways
5.1. Inhibition of mRNA maturation
An important ﬁnding was BARD1’s interaction with the mRNA
polyadenylation factor CstF-50 (cleavage stimulation factor), a pro-
tein complex involved in the polyadenylation and 3′end cleavage of
mRNAprecursors (Kleiman andManley, 1999). The BARD1-CstF-50
interaction was induced by DNA damage and inhibited polyadeny-
lation in vitro. A BARD1 mutation Q564H, associated with breast
and ovarian cancers, resulted in reduced binding to CstF-50 and
diminished inhibition of polyadenylation (Kleiman and Manley,
2001). The CstF-50 binding site on BARD1 is located within the
ANK repeats and theBRCTdomains of BARD1 (Kleiman andManley,
1999). The interaction of BARD1 with CstF-50 is regulated by phos-
phorylation of BARD1 at Thr(714) in vivo by ataxia-telangiectasia
(ATM), a DNA damage-induced kinase (Kim et al., 2006). These
results place BARD1 in a pathway from genotoxic signaling to inhi-
bition of mRNA maturation.
5.2. A role in p53 stability and apoptosis
The BARD1 C-terminal half is a module for various interactions
(Fig. 3). BARD1binding to CstF-50was shown to be competed for by
the tumor suppressor p53 (Nazeer et al., 2011), which also binds
to the BARD1 ANK repeats and the region between the ANK and
BRCT domains (Jefford et al., 2004). Genotoxic stress caused BARD1
mRNA and protein upregulation. BARD1 was found to bind and
stabilize p53 and induce apoptosis, but BRCA1 antagonized BARD1-
induced apoptosis (Feki et al., 2005; Irminger-Finger et al., 2001).
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Several reports addressed the complexity of the BARD1-p53
xis, in particular the aspect of BARD1 or BRCA1 interaction with
53 (Fabbro et al., 2004a, 2004b; Jiang et al., 2011; Rodriguez et al.,
004; Tembe and Henderson, 2007b).
.3. BARD1 involvement with pathways of oncogenesis
A speciﬁc role for BARD1 in tumorigenesis might exist in cer-
ical cancer. Some strains of the human papillomaviruses (HPVs)
re the accepted cause of cervical cancer. The major oncogenic
iral protein, HPV E6, acts by binding and sequestering p53. BARD1
as identiﬁed as a binding partner of E6 (Yim et al., 2007). BARD1
xpression repressed E6 action in cervical cancer cells, suggesting
hat BARD1 has tumor suppressor functions and BARD1 deﬁciency
ight promote HPV-induced cervical carcinogenesis.
Another role in tumorigenesismight be based on the interaction
f the BARD1 C-terminus with the N-terminus of the Ewing’s sar-
oma (EWS) gene product and the transforming oncogenic fusion
rotein EWS-FLI1 in vitro and in vivo (Spahn et al., 2002). Whether
inding to BARD1 affects EWS-FLI1 transforming capacity has not
et been investigated.
BARD1 interacts with the transcription factor NF-B (Dechend
t al., 1999). A C-terminal fragment of BARD1, spanning the ANK
hrough the BRCTdomains binds in vitro to theANK repeats domain
f Bcl-3, a NF-B inhibitor. Incorrect regulation of NF-B has been
inked to cancer and inﬂammatory and autoimmune diseases, and
ight involve BARD1.
Recently, BARD1 emerged as the key player in poly(ADP-ribose)
PAR) signaling after DNA damage (Li and Yu, 2013). Protein PARy-
ation is a ﬁrst step in DNA double strand break repair. The BARD1
RCTdomains bind to PAR and thus recruit the BARD1-BRCA1 com-
lex to DNA damage sites. This pathway is particularly interesting
ecause of the promising anti-cancer drugs acting on inhibiting the
AR polymerizing enzyme PARP1, which seem more efﬁcient in
ells with BRCA1 mutations.
. Genetic and epigenetic modiﬁcations of BARD1 in cancer
It is nearly 20 years that the BRCA1 and BRCA2 genes were dis-
overed as breast and ovarian cancer predisposition genes (Miki
t al., 1994; Wooster et al., 1994). Tweny to 25 percent of familial
reast cancer cases are associated with causative genetic modiﬁca-
ions, in BRCA1 or BRCA2. The remaining hereditary breast cancer
ases are linked to rare mutations or common single nucleotide
olymorphisms (SNPs) in other genes, including BARD1.
The strong evidence for BRCA1 and BRCA2 as predisposition
enes is basedongermlinemutations inprotein codingexons.More
han 1700 such variants have been identiﬁed in BRCA1 and 2000
n BRCA2 [https://research.nhgri.nih.gov/projects/bic]. Mutations
n protein coding exons of BARD1 were signiﬁcantly less frequent
Fig. 4; Table 2), suggesting that cells with such BARD1 mutations
re non-viable. However, with advances in deep sequencing and
hole genome sequencing, an ever-increasing number of polymor-
hisms andSNPs in theBARD1 gene associatedwith various cancers
s being identiﬁed.
.1. Breast cancer-associated variations of BARD1
The ﬁrst missense mutations (p.Q564H, p.V695L, and p.S761N)
dentiﬁed in the BARD1 gene localized to the C-terminal part of the
rotein (Thai et al., 1998) and established BARD1’s role as a tumor
uppressor.Several mutations were described within BARD1 in an Ital-
an cohort of familial breast and ovarian cancers without BRCA1
nd BRCA2 gene alterations, including three missense muta-
ions, p.K312R, p.C557S, p.N295S, one in-frame deletion of sevenf Biochemistry & Cell Biology 72 (2016) 1–17
amino acid residues, c.1075 1095del21 (p.Leu359 Pro365del), and
a c.1579C>G transversion with no amino acid change at position
p.A502, indicative of a novel polymorphism (Ghimenti et al., 2002).
The mutations p.C557S and c.1075 1095del21 were considered as
polymorphisms by Thai et al. (1998). Japanese patients with famil-
ial breast cancers negative for BRCA1 or BRCA2 germline mutations,
revealed six alterations in BARD1, comprising four missense muta-
tions (p.S241C, p.R378S, p.N470S, p.V507M), one silent mutation
(p.H506H), and one in-frame deletion (c.1075 1095del21) (Ishitobi
et al., 2003).
A c.1291A>G polymorphism, which translates into an arginine
instead of glutamine (p.Q406R), was identiﬁed in three out of ten
ovarian cancers (Wu et al., 2006). A genotyping analysis of three
non-synonymous SNPs, p.P24S, p.R378S, p.V507M in a case-control
studyof507patientswith sporadicbreast cancer inChinesewomen
indicated that the polymorphisms p.P24S and p.R378S in BARD1
may jointly contribute to the susceptibility of breast cancer (Huo
et al., 2007). Neither the p.C557S nor the p.V507M alterations were
signiﬁcantly associated with familial or sporadic breast cancer in
the Finnish population (Vahteristo et al., 2006).
The screeningof 196non-BRCA1/2breast or ovarian cancer fam-
ilies forBARD1germlinemutations identiﬁedeleven intronvariants
and ﬁfteen exon variants, comprising nine missense mutations,
four silent mutations, one in-frame deletion and one frame-shift
duplication (c.1935 1954dup; p.E652Vfs*69) causing a premature
stop and loss of the second BRCT domain of BARD1 (De Brakeleer
et al., 2010). Four alterations, namely p.V85L, c.1203T>C, p.I509T,
and p.E652Vfs*69, were novel.
Of all BARD1 variants, p.C557S, residing between the ANK and
BRCT domains of BARD1 is the most studied missense mutation
(Fig. 4). There is strong evidence that p.C557S is associated with
breast cancer risk (Ghimenti et al., 2002; Karppinen et al., 2004,
2006; Stacey et al., 2006). The risk of breast cancer was speciﬁ-
cally increased in double carriers of the BARD1 p.C557S and the
BRCA2 c.771 775del5 mutations and was considered 3-fold greater
than the risk for women with only the BRCA2 c.771 775del5 allele
(Stacey et al., 2006). However, other studies did not show a correla-
tion of the p.C557S variant with breast or ovarian cancer (Gorringe
et al., 2008; Jakubowska et al., 2008; Johnatty et al., 2009; Spurdle
et al., 2011; Vahteristo et al., 2006), further conﬁrmed by a meta-
analysis of 20,000 cases and controls (Ding et al., 2011). These
discrepancies might be due to population substructure or might
indicate that BARD1 mutations or variants could be deleterious in
combination with other genetic changes.
A more complex analysis of BARD1 modiﬁcations in BRCA1/2-
negative high-risk breast and/or ovarian cancer patients from
Poland identiﬁed 16 different BARD1 variants, ﬁve of which were
novel. Three of them were potentially pathogenic, including a pro-
tein truncating nonsense mutation (c.1690C>T, p.Q564*), a splice
mutation (c.1315-2A>G) resulting in exon 5 skipping, and a silent
change (c.1977A>G) which alters several exonic splicing enhancer
motifs in exon 10 and results in a transcript lacking exons 2-9
(Ratajska et al., 2012). In a recent study, three BARD1 mutations
were identiﬁed that alter splicing leading to skipping of exons 5, 8,
and 2-9, respectively (Ratajska et al., 2015).
A BARD1 germline mutation with loss of heterozygosity in the
tumor was found in a patient negative for BRCA1 or BRCA2 muta-
tions (Sabatier et al., 2010). DNA array expression proﬁle of the
cancer showed that it resembled thebasal-like andBRCA1-mutated
phenotypes.
In a gene-sequencing project, BRCA1 or BRCA2 germline muta-
tions were found in 18 percent of ovarian cancers and BARD1
germline mutations in six percent (Walsh et al., 2011) (Fig. 4). This
is a much higher proportion of mutations in BARD1 than identiﬁed
in previous studies reporting mutations in protein-coding exons
only, suggesting that cancer-associated BARD1 variations might be
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Fig. 4. Mutations and polymorphisms of BARD1. Intron/exon structure of BARD1 is shown on the top with corresponding cDNA and amino acid (codons) residues above.
The protein structure is shown with phosphorylation sites (P), RING, ANK, and BRCT motifs below. Arrows mark mutations with circles for missense (yellow) and Nonsense
(red) mutations. Deletions/duplications are marked as triangles for in-frame (blue) and frame shift (red). Squares mark silent mutations (blue). Red stars indicate splicing
mutations and green stars SNPs within introns. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 2
BARD1 mutations and variants.
Position Exon Mutation (CDS) Mutation (AA) Mutation ID (COSM) No. of
records
Mutation type Type of cancer Splicing prediction result
21 1 c.61C>T p.R21C COSM399095 1 Sub. missense Lung Low probability
85 3 c.253G>A p.V85M COSM159329 1 Sub. missense Breast Low probability
104 3 c.312G>C p.M104I COSM476870 1 Sub. missense Kidney Rather low probability
140 4 c.420G>T p.K140N COSM256387 1 Sub. missense Large intestine Very high probability
162 4 c.484T>G p.S162A COSM145130 1 Sub. missense Haematopoietic
and lymphoid
tissue
Rather low probability
163 4 c.487G>A p.V163M COSM48253 1 Sub. missense Lung Rather low probability
174 4 c.521G>T p.S174I COSM402165 1 Sub. missense Lung Low probability
183 4 c.547G>C p.V183L COSM266081 1 Sub. missense Large intestine Low probability
192 4 c.575C>T p.S192F COSM573326 1 Sub. missense Large intestine Rather low probability
249 4 c.747C>T p.I249I COSM1129335 1 Sub. synonymous Prostate Rather low probability
254 4 c.760A>T p.I254L COSM573327 1 Sub. missense Lung Low probability
276 4 c. 825 829delAACTG p.T276fs*7 COSM238943 1 Del. frameshift Prostate Very high probability
287 4 c.859G>T p.E287* COSM172763 1 Sub. nonsense Large intestine Low probability
344 4 c.1032T>G p.S344R COSM720079 1 Sub. missense Lung Rather low probability
352 4 c.1056G>A p.V352V COSM365762 1 Sub. synonymous Lung Rather low probability
411 4 c.1232C>A p.P411H COSM720080 1 Sub. missense Lung Rather low probability
413 4 c.1237G>A p.A413T COSM720081 1 Sub. missense Lung High probability
439 5 c.1317C>T p.G439G COSM309429 1 Sub. synonymous Lung Rather low probability
441 5 c.1323A>G p.I441M COSM209927 1 Sub. missense Large intestine Rather low probability
452 5 c.1356T>G p.S452R COSM141016 1 Sub. missense Upper
aerodigestive
tract
Rather low probability
456 5 c.1366G>A p.V456I COSM243168 1 Sub. missense Prostate Low probability
460 5 c.1378G>A p.A460T COSM209926 1 Sub. missense Large intestine Rather low probability
489 6 c.1466C>T p.T489I COSM225501 1 Sub. missense NS High probability
490 6 c.1468A>C p.T490P COSM339124 1 Sub. missense Lung High probability
491 6 c.1471G>T p.G491W COSM720082 1 Sub. missense Lung High probability
515 6 c.1543T>G p.S515A COSM377218 1 Sub. missense Lung Rather low probability
523 6 c.1567G>A p.V523I COSM476869 1 Sub. missense Kidney Low probability
558 7 c.1674A>T p.S558S COSM720083 1 Sub. synonymous Lung Rather low probability
576 8 c.1727G>T p.G576V COSM400590 1 Sub. missense Lung Very high probability
597 8 c.1791T>C p.Y597Y COSM1016065 1 Sub. synonymous Endometrium Rather low probability
602 8 c.1805G>T p.S602I COSM48252 1 Sub. missense Lung Very high probability
648 10 c.1942G>T p.E648* COSM573328 1 Sub. nonsense Lung Very high probability
660 10 c.1980C>G p.S660R COSM720085 1 Sub. missense Lung Low probability
665 10 c.1995A>G p.E665E COSM243167 1 Sub.synonymous Prostate Low probability
665 10 c.1995A>T p.E665D COSM250848 1 Sub. missense Liver Low probability
674 11 c.2021G>T p.G674V COSM324796 1 Sub. missense Lung High probability
679 11 c.2037G>T p.L679F COSM176125 1 Sub. missense Large intestine Low probability
680 11 c.2039G>A p.W680* COSM270687 1 Sub. nonsense Large intestine Very high probability
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ore frequent in non-coding sequences than in coding exons. All
tudies so far concentrated on penetrance of BARD1 mutations in
oth sporadic andnon-BRCA1/2 familial breast andovariancancers.
hether BARD1 aberrations contribute to BRCA1/2-associated
reast/ovarian cancer predisposition has not been speciﬁcally
nvestigated.
An alternative to the single gene predisposition was reported
y Onay and colleagues (Onay et al., 2006), showing a signiﬁcant
nteraction between BARD1-[Pro24Ser] and XPD-[Lys751Gln] in a
olygenicmodel of SNPs of lowpenetrance. Such approachesmight
dentify links of BARD1 SNPs with different pathways.
.2. BARD1 variations associated with neuroblastoma and other
ancers
Three common nonsynonymous SNPs in BARD1 coding regions,
.P24S, p.R378S and p.V507M, which were described in breast
nd/or ovarian cancers, showed statistically signiﬁcant association
ith high-risk neuroblastoma (NB) by a SNP-based genome-wide
ssociation study (GWAS), suggesting that SNPs in BARD1 are not
nly important for breast and ovarian cancer, but also for other
ancers (Capasso et al., 2009, 2013; Nguyen le et al., 2011).
Interestingly, the c.C143T (p.P24S) variation might not induce
tructural changes, but it alters a potential Kozak motif in front
f an alternative translation initiation ATG or an ATG used in an
lternative open reading frame (ORF) speciﬁc for spliced isoform
ARD1 (Fig. 5).
ig. 5. The BARD1 SNPs associated with neuroblastoma. (A) The signiﬁcant SNPs identiﬁe
lternative splicing, e.g. BARD1 or BARD1. Mutations in coding regions were not sign
f exon 1 is shown with mutation C134T/P24S (yellow) and aligned protein sequences o
f a potential Kosak motif are indicated above. The P24S mutation might diminish tran
nterpretation of the references to color in this ﬁgure legend, the reader is referred to thef Biochemistry & Cell Biology 72 (2016) 1–17
Most importantly, the SNPs with highest correlation scores
with NB were found in the 5′ untranslated and in intronic regions
of BARD1 (Capasso et al., 2009). The position of these SNPs and
their strong linkage disequilibrium suggested that they might
be associated with an alternative splicing mechanism (Fig. 5).
This hypothesis was conﬁrmed by the demonstration of increased
expression of a spliced isoform BARD1 in NB cells carrying the
disease-linked SNP allele (Bosse et al., 2012).
Other independent studies on NB in African American patients
associated ﬁve SNPs in the BARD1 region with cancer risk (Latorre
et al., 2012). BARD1 SNPs emerged as the most strongly associated
withNB in a comparative study of NB risk loci (Capasso et al., 2013).
An analysis of several independent studies revealed that 31 path-
ways and ten genes are involved in NB, of which BARD1 and IL3 are
the two most important ones (Lee et al., 2014b).
BARD1 alterations were also found associated with other can-
cers and diseases. SNPs or deletions were found associated with
myeloproliferative neoplasm (Tenedini et al., 2014), oral cancer
(Cengiz et al., 2007), colon cancer (Esteban-Jurado et al., 2015), and
predisposition to schizophrenia (van Schijndel et al., 2009).
7. Differentially spliced BARD1 isoforms in cancer
Alternative splicing is an important mechanism for the gen-
eration of multiple varying mRNA and protein isoforms from a
single primary transcript, adding to protein diversity and regula-
tion of gene expression (Kornblihtt, 2007). In humans, over 80% of
genes are alternatively spliced (Matlin et al., 2005). Furthermore,
d in a GWAS are located in introns (Capasso et al., 2009). SNPs in introns promote
iﬁcant. (B) Exon structure of FL BARD1 and of spliced isoforms. (C) DNA sequence
f BARD1 ORF and alternative ORF of BARD1. The conserved (enlarged) positions
slation from the BARD1 ORF and promote translation from alternative ORF. (For
web version of this article.)
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Fig. 6. Structure of BARD1 and spliced isoforms. FL BARD1 exon structure (blue) is aligned with spliced BARD1 isoforms below and protein structure above. Spliced variants
are named with Greek letters (left) as published for isoforms expressed in gynecological and lung and colon cancers. Presumed protein coding exons of isoforms are shown
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upregulated BARD1 expression associated with NB (Bosse et al.,
2012) and poor survival of lung and colon cancer patients (Zhangn green, noncoding exons white, and alternative open reading frames (,  and )
eferred to the web version of this article.)
lternative splicing-derived protein isoforms could have aberrant
r antagonistic functions. Such variants, in particular BARD1 vari-
nts, with dominant negative roles have speciﬁcally been found
ssociated with cancer (Chen and Weiss, 2014).
Several splice variants have been identiﬁed for BRCA1 (ElShamy
nd Livingston, 2004; Pettigrew et al., 2010), and BRCA1 muta-
ions causing splicing were found associated with breast cancer
Thomassen et al., 2012). BARD1 generates several transcripts by
lternative splicing (Fig. 6), which are highly expressed in various
ancers (Bosse et al., 2012; Feki et al., 2004, 2005; Lepore et al.,
013; Li et al., 2007a, 2007b; Pilyugin and Irminger-Finger, 2014;
porn et al., 2011; Wu et al., 2006; Zhang et al., 2011, 2012b). In
inewith its function as tumor suppressor, BRCA1 is very frequently
ethylated in cancer. BARD1 promotermethylationwas found nei-
her in breast (Li et al., 2007b) nor in more than 140 colon cancer
ases (Zhang et al., 2012b). These ﬁndings suggest that BRCA1 loss-
f-functions, due tomutations or silencing, and aberrant splicing of
ARD1 and gain-of dominant negative functions, is associated with
ancer.
Interestingly, BARD1 isoformswere also found highly expressed
n human choriocarcinoma and in invasive cytotrophoblasts where
heir expression is controlled by hypoxia and hormones (Li et al.,
007a).
BARD1 isoforms were detected in different gynecological can-
ers (Li et al., 2007b;Wu et al., 2006). Cloning of BARD1 cDNAs from
reast, ovarian, endometrial, and cervical cancers showed that a
umber of protein coding isoforms, termed , , , , , 	, 
, , ,
enerated by differential splicing and alternative initiation of tran-
cription, were expressed in all of these cancers, but the relative
xpression levels of speciﬁc isoforms were different in different
ypes of cancer (Fig. 6). BARD1 isoforms were expressed in most
reast cancer samples (Lombardi et al., 2007) and correlated with
oor prognostics for breast and ovarian cancer (Li et al., 2007b).
BARD1 isoforms ﬁrst described in gynecological cancers were
lso identiﬁed in non-small-cell-lung cancers (NSCLC) and colo-
ectal cancers (Sporn et al., 2011; Zhang et al., 2012a, 2012b).
nterestingly, two novel isoforms,  and (Fig. 6), were speciﬁcally
orrelatedwith the transition fromconﬁned to invasive tumors and
orrelated with poor prognosis and reduced patient survival time
n lung and colon cancer (Zhang et al., 2012a, 2012b).
All spliced BARD1 mRNA isoforms were also reported for NB
Bosse et al., 2012). In particular, twoNSPs in BARD1 introns 1 and 3
Capasso et al., 2009) provided a propensity for differential splicingow. (For interpretation of the references to color in this ﬁgure legend, the reader is
of the corresponding exons 2 and 3. Indeed, the BARD1 isoform
was highly upregulated in NB and in tumor-derived cell lines with
the SNP haplotype (Bosse et al., 2012) (Fig. 5).
Interestingly, all BARD1 isoforms lack either the RING ﬁnger or
ANK repeats, or both, which are required for the tumor suppressor
functions (Fig. 6).
7.1. BARD1ˇ, the oncogenic driver
BARD1 splice variants BARD1 and BARD1were ﬁrst observed
in rat spermatocytes and in a rat ovarian cancer cell line NuTu-19
(Feki et al., 2004, 2005). Both isoforms were highly overexpressed
together in the NuTu-19 cells, while no FL BARD1 could be detected
in these cells neither on the mRNA nor the protein level. NuTu-19
cells are highly tumorigenic and resistant to apoptosis (Feki et al.,
2005), suggesting that neither BARD1 nor BARD1 can substitute
for the tumor suppressor functions of FL BARD1.
BARD1, characterized by lack of exons 2 and 3, translates from
an alternative ORF in exon 1 into a protein lacking the RING ﬁnger
and BRCA1 interaction. Speciﬁc selective repression of BRCA1, FL
BARD1, or BARD1, showed that cell proliferationwas only slightly
affected by FL BARD1 or BRCA1 repression, but repression of FL
BARD1 and/or BARD1 lead to a dramatic block of cell proliferation
and of cell cycle progression (Bosse et al., 2012; Ryser et al., 2009).
Functional studies revealed that BARD1 has a dominant negative
function in stabilizing theAurora kinasesAandB (Bosse et al., 2012;
Ryser et al., 2009). BARD1 scaffolds Aurora B and BRCA2 at the
midbody during telophase and cytokinesis, antagonizing Aurora B
ubiquitination and degradation by the FL BARD1-BRCA1 E3 ubi-
quitin ligase. This results in a similar phenotype as reported for a
BRCA2 mutation that affects arrest in cytokinesis (Daniels et al.,
2004). Excess BARD1 has a pro-proliferative function by overrid-
ing the mitotic checkpoint, as shown in vitro for non-transformed
ﬁbroblasts, and leads to an invasive phenotype (Bosse et al., 2012).
The notion of BARD1 as driver of tumorigenesis is supported byet al., 2012a, 2012b). A recent study of BARD1 isoform expression
in breast cancer reported BARD1more frequently overexpressed
than BARD1, although not conﬁrmed on the protein level (Wiener
et al., 2015).
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.2. BARD1ı interferes with estrogen signaling
Another functional isoform involved in tumorigenesis is
ARD1, characterized by deletion of exons 2-6which encodemost
f the RING ﬁnger and the ANK repeats. BARD1 does not inter-
ct with BRCA1, whereas it interacts and co-localizes with CstF-50
o cytoplasmic dots in HeLa cells (Tsuzuki et al., 2006). Intracel-
ular localization studies showed that BARD1 co-localized with
itochondria (Tembe and Henderson, 2007a). Unlike FL BARD1,
soform BARD1 did not stimulate apoptosis or alter membrane
ermeability, but might have a function in regulation of mitochon-
rial response to stress (Tembe and Henderson, 2007a).
BARD1mRNAwas expressed in all breast, ovarian, uterine, and
ervical cancer cell lines, as well as in tissues of gynecological can-
ers, lung and colon cancer (Li et al., 2007b; Wu et al., 2006; Zhang
t al., 2012a, 2012b). It was the only abundantly expressed isoform
n cervical cancer and clear cell ovarian carcinoma (Li et al., 2007b).
It was shown that speciﬁcally BARD1 binds ER and antag-
nizes FL BARD1 in degradation of ER, while the BRCA1-BARD1
biquitin ligase controls ER turnover (Dizin and Irminger-Finger,
010; Eakin et al., 2007). As BRCA1 and BARD1 expression is upre-
ulated by estrogen via ER (Creekmore et al., 2007; Dizin and
rminger-Finger, 2010), this constitutes a regulatory feedback loop.
owever, estrogen also induces as expression of BARD1 isoforms,
ncluding BARD1, and as BARD1 binds to ER more efﬁciently
han FL BARD1, high levels of BARD1 will lead to stabilization or
o even higher levels of ER and therefore to increased response to
strogen (Dizin and Irminger-Finger, 2010).
.3. BARD1 is upregulated in leukemia
ABARD1 isoformcontainingonly exons6 to11, BARD1, encod-
ng ANK repeats and BRCT domains, is highly upregulated in acute
yeloid leukemia (AML)andAMLcell lines (Leporeet al., 2013). The
peciﬁc promoter of BARD1 has not been identiﬁed. Interestingly
he expression of BARD1 is downregulated by HDAC inhibitors
HDACi) that also upregulate microRNAs, comprising miR-19a and
iR-19b, which speciﬁcally bind to the BARD1 3′UTR.
BARD1 overexpression induced multiple mitotic defects,
ncludingmultipolar spindles, but inhibitedapoptosis (Lepore et al.,
013). Thus, BARD1 acts as an oncogene.
. Complex regulation of BARD1 expression
BARD1 expression is regulated on different levels. On the mRNA
evel BARD1 expression is controlled by various signaling pathways
Andre et al., 2015), as well as by cell cycle regulated transcription
actors (E2F4) (Ren et al., 2002), and increases during S-phase.
On the protein level, BARD1 protein stability is regulated by sta-
ilizing phosporylation and by degrading and/or cleaving enzymes
Chen et al., 2002; Gautier et al., 2000). BARD1 stability is increased
y phosphorylation during the cell cycle, and hyperphosphory-
ated forms are prevalent during M-phase (Choudhury et al., 2005).
yclin-dependent kinase 2/cyclin A1 and E1 target BARD1 and
ffect its stability and heterodimer functions with BRCA1 (Hayami
t al., 2005).
While BRCA1 is targeted for degradation by ubiquitination-
ependent pathways (Choudhury et al., 2004; Rodriguez et al.,
004; Wu et al., 2010), BARD1 is one of four proteins that are
egraded in a cell cycle regulatedmanner by the anaphase promot-
ng complex (APC/C) (Song and Rape, 2010). Another proteolytic
odiﬁcation of BARD1 occurs during apoptosis, namely cleavage
y the calpain protease (Gautier et al., 2000). Thus, BARD1 levels
ncrease during S-phase, due to transcriptional upregulation and
ncreased protein stability, reaching a peak in mitosis.f Biochemistry & Cell Biology 72 (2016) 1–17
Another inducer of BARD1 expression is estrogen via ER
(Creekmore et al., 2007). The hormone-induced expression of
BRCA1 andBARD1or BARD1 isoformsmight provide a link that par-
tially explains the increased riskofbreast/ovariancancer associated
with BARD1 or BRCA1 deﬁciencies and estrogen exposure.
Upregulated expression of BARD1 was also associated with
hypoxic conditions andwith response to genotoxic cellular stress in
different mouse tissues (Irminger-Finger et al., 2001; Jefford et al.,
2004; Li et al., 2007a). In tumor tissues, FL BARD1 is underrep-
resented or not present, while differentially spliced isoforms are
over-expressed and associated with carcinogenesis. Understand-
ing the regulation of expression of FL BARD1 and its isoforms is
therefore of utmost importance.
The expression of the majority of protein-coding BARD1 iso-
forms is driven by the bona ﬁde promoter located upstream of exon
1 of BARD1 (Li et al., 2007b). According to the analysis of chromatin
modiﬁcation associated with transcription, this promoter appears
to be active in the majority of tissues reported in public databases
(Pilyugin and Irminger-Finger, 2014). It was also shown that the
expression of BARD1 is positively regulated by estrogen. However,
the estrogen response element (ERE) was identiﬁed in intron 9 of
BARD1 (Creekmore et al., 2007; Dizin and Irminger-Finger, 2010).
Interestingly, this ERE is located 73kb downstream of the bona ﬁde
BARD1 transcription start site but in the proximity of the transcrip-
tion start site of a non-coding BARD1 isoform BARD1 9′L (Fig. 7).
In healthy individuals, modiﬁcations associated with active tran-
scription from the BARD1 9′L promoter were only observed in B
lymphocytes and endothelial cells. However, in cancer cell lines
and human cancers BARD1 9′L is highly expressed (Pilyugin and
Irminger-Finger, 2014).
BARD1 9′L shares 3′end sequences with protein-coding BARD1
mRNAs and could function as competing endogenous RNA (ceRNA),
regulating the expression of BARD1mRNAs (Pilyugin and Irminger-
Finger, 2014). ceRNAs represent one type of the recently emerged
functional long non-coding RNAs (lncRNA), which share microRNA
recognition elements with speciﬁc mRNAs and can compete for
microRNAbinding and thus affect the stability and functionof these
mRNAs (Panzitt et al., 2007; Poliseno et al., 2010; Salmena et al.,
2011).
Available data suggest that the 250nucleotides after the transla-
tion stop codon of the BARD1 3′UTR are a minimal fragment of the
BARD1 3′UTR shared by FL BARD1 and shorter oncogenic BARD1
mRNA isoforms (Pilyugin and Irminger-Finger, 2014). However,
FL BARD1 has a much longer 3′UTR and may be down-regulated
by microRNAs seeding in the region that oncogenic BARD1 iso-
forms are lacking (Fig. 7). As a result, the ratio of FL BARD1 versus
isoforms may be shifted in favor of oncogenic BARD1 isoforms,
thus driving carcinogenesis. There is accumulating evidence that
links the BARD1 3′UTR to microRNAs and cancer. One example
for such regulation is BARD1 SNP rs7585356, which is associated
with NB (Capasso et al., 2009) and modiﬁes the overlapping tar-
get sequence of several microRNAs and potentially affects their
binding and the microRNA-dependent regulation of expression
of BARD1 and its isoforms in NB (Pilyugin and Irminger-Finger,
2014).
Furthermore, BARD1 9′L has been shown to compete for
microRNA binding in the case of miR-101 and miR-203 in vitro
(Pilyugin and Irminger-Finger, 2014). Similarly, miR-19a and
miR-19b were reported to down-regulate the expression of the
cancer-associated BARD1 isoform in acute myeloid leukemia and
might be inhibited by a ceRNA-dependent regulation of BARD1
expression (Lepore et al., 2013).
Changes in the epigenetic and hormone-dependent gene regu-
lation accompanying carcinogenesis might activate the expression
of BARD1 9′L in cancer cells, thus promoting stability of oncogenic
BARD1 isoforms.
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Fig. 7. Regulation of FL BARD1 and isoforms by microRNAs and BARD1 9′L. (A) Genome structure and 3′UTR region of FL BARD1 is shown with arrows indicating positions of
transcription start sites from common promoter of FL BARD1 and isoforms and BARD1 9′L promoter. A scheme of cDNA structures of FL BARD1 and isoforms, including BARD1
9′L (ceRNA 9′L), is presentedwith respective 3′UTRs and themicroRNAs targeting different regions of the UTRs:miRs-250, binding to the 250 bases after the stop codon,miRs-
3000, binding to the longer 3′UTR of FL BARD1. (B) Model for microRNA and BARD19′L regulation of FL BARD1 and isoform expression. Combinations of microRNAs targeting
3′UTR positions 1–250 (miRs-250) or positions 251–3000 (miRs-3000), are expressed in a tissue-speciﬁc manner and effect repression of FL BARD1 as well as isoforms. FL
BARD1 contains a long 3′UTR (positions 1–3000), but isoforms tend to have shorter 3′UTRs (BARD1, BARD1, and BARD1). In healthy tissues (Normal) microRNAs maintain
a ic inst ′
p , thus
i A repa
9
n
f
t
o
a
t
i
d
a
r
c
g
t
t
i
r
c
e
p
a
9
b
f
i
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romoter is active, BARD1 9′L competes for binding of miR-250s, but not miR-3000s
soforms antagonize FL BARD1 functions, this leads to genetic instability, loss of DN
. Therapeutic possibilities
BARD1 isoforms are highly upregulated in cancer cells antago-
izing the functions of FL BARD1. In normal cells FL BARD1 has a
unction in turnover of themitotic Aurora kinases,which are essen-
ial for proper cell division. Overexpression of Aurora kinases is
bserved in many cancers and is associated with genetic instability
nd aneuploidy, which makes the Aurora kinases emerging drug
argets (Marzo and Naval, 2013; Wang et al., 2009). The switch-
ng from FL BARD1 to BARD1 permits to override cell cycle blocks
ue to the deregulated turnover of the Aurora kinases. Thus, Aurora
nd BARD1 expression levels might be predictive biomarkers for
esponse to Aurora inhibitors.
Estrogen is the major risk factor for breast and ovarian can-
er and anti-estrogen preventive measurements are proposed for
enetically predisposed women. Estrogen acts via ER in activa-
ion of transcription and cell cycle progression. The caveat exists
hat most breast cancers with BRCA1 mutations are ER negative. It
s noteworthy that in ER positive cells BARD1 is upregulated in
esponse to estrogen, but in ER negative cells, BARD1 is expressed
onstitutively (Dizin and Irminger-Finger, 2010). This might be
xplained by the presence of a repressor, which is activated in ER
ositive cells, but lost in ER negative cells. This repressor could be
BARD1 3′UTR binding microRNA, or the competing ceRNA BARD1
′L. Inhibiting BARD1 isoform expression or/and BARD1 9′L might
e a novel pathway for therapeutic intervention or/and prevention
or predisposed women.
PARP inhibitors (PARPi) are the group of pharmacological
nhibitors of the enzyme poly ADP ribose (PAR) polymerase (PARP)
sed for the treatment of cancer. UponDNAdamage, PARP proteinsability, DNA repair, and cell cycle control functions. In cancer cells, the BARD1 9 L
creating a disequilibrium in favor of BARD1 isoforms with a short 3′UTR. As BARD1
ir and cell cycle control functions, and permits uncontrolled proliferation.
recruit DNA repair proteins, in particular BRCA1 and BARD1. There-
fore, PARPi causemultiple double strandbreaks, and in tumorswith
BRCA1 or BRCA2 mutations these double strand breaks are even
less efﬁciently repaired, leading to more rapid cell death (Lee et al.,
2014a).
The BRCA ﬁeld was focused on investigating mostly the role
of BRCA1, BRCA2, and less so of BARD1, in DNA recombination
and DNA repair pathways. However, the ﬁnding that BARD1 binds
to PAR and guides PARP to the side of DNA repair (Li and Yu,
2013), brings BARD1 in the center of mechanisms that are impor-
tant forunderstanding thePARPi-mediated therapies. Todetermine
how the expression of BARD1 isoforms contributes to the success
of PARPi therapy will be crucial, as BARD1 isoforms are highly
expressed in BRCA1 mutation-linked tumors (Wu et al., 2006).
10. Co-evolution of BRCA1, BARD1, and BARD1 isoforms?
As pointed out above, BARD1 and BRCA1 share homologies in
the N and C-terminus comprising the RING motif and the BRCT
domains, but no homology is found for the middle regions. The
N and C-termini of both proteins are not only homologous, but
also have conserved intron–exon junctions in different species
(Irminger-Finger and Leung, 2002). While these similarities sug-
gest a common evolutionary ancestor for BARD1 and BRCA1, there
are additional factors that indicate a separate, but converging, evo-
lution.Protein sequence alignment of BARD1 translation products of
different species shows that the BARD1N-terminus is lesswell con-
served than the C-terminus (Fig. 2). BARD1 protein sequences from
different species show little or no homology within the regions
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pstream of the RING ﬁnger motif. In many species, protein trans-
ation starts at the second methionine of the human sequence, and
n some cases the translation start-encoding exon 1 has no rela-
ionship with human exon 1 (e.g. BARD1 canis lupus exons 1 is not
elated to human BARD1), or the RING ﬁnger motif is degenerated
BARD1 arabidopsis). From this one might conclude that a BARD1
rotein existed as anANK and BRCT containing protein and evolved
nd acquired the RING ﬁnger.
Interestingly, all BARD1 isoforms lack either RINGor ANKmotifs
r both, but not the BRCT domains. Furthermore, BARD1 iso-
orms are not unique to cancer cells. Indeed, BARD1 isoforms are
ighly expressed in human cytotrophoblasts and are associated
ith cytotrophoblast invasion and proliferation (Li et al., 2007a).
hether isoforms are essential for successful cytotrophoblast
nvasion remains to be determined. One might hypothesize that
soforms comprising the BRCT domains, or BRCT and ANK, existed
s separate genes, and exon shufﬂing during evolution generated
gene coding for RING, ANK, and BRCT domains, with tumor sup-
ressor functions. Different evolutionary trees are indeed found for
he BRCT domains of BARD1 and BRCA1 (Sheng et al., 2011).
It is possible that BRCT containing truncated forms of BARD1
re archaic forms of BARD1. As it is established that BRCA1 needs
ARD1 for stability, intracellular localization, and tumor suppressor
unctions, one might ask: Does BARD1 need BRCA1? This remains
o be elucidated.
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